Effects of ribavirin and/or IVIG on progression to pneumonia and death
| Type of patients . | Outcomes . | Ribavirin (with/without IVIG) . | IVIG alone . | No treatment . | P . |
|---|---|---|---|---|---|
| Leukemia (n = 80) | n = 9 | n = 6 | n = 69 | ||
| Progression to pneumonia in patients treated at URI stage, N (%) | 6/6 (100) | 1/5 (20) | 42/69 (61) | .02* | |
| Death within 30 days of follow-up, N (%) | 1/9 (11) | 0/6 (0) | 7/65 (11) | > .99 | |
| HSCT (n = 120) | n = 10 | n = 30 | n = 80 | ||
| Progression to pneumonia in patients treated at URI stage, N (%) | 3/5 (60) | 5/21 (24) | 38/94 (40) | .27 | |
| Death within 30 days of follow-up, N (%) | 1/10 (10) | 3/29 (10) | 4/69 (6) | .52 |
| Type of patients . | Outcomes . | Ribavirin (with/without IVIG) . | IVIG alone . | No treatment . | P . |
|---|---|---|---|---|---|
| Leukemia (n = 80) | n = 9 | n = 6 | n = 69 | ||
| Progression to pneumonia in patients treated at URI stage, N (%) | 6/6 (100) | 1/5 (20) | 42/69 (61) | .02* | |
| Death within 30 days of follow-up, N (%) | 1/9 (11) | 0/6 (0) | 7/65 (11) | > .99 | |
| HSCT (n = 120) | n = 10 | n = 30 | n = 80 | ||
| Progression to pneumonia in patients treated at URI stage, N (%) | 3/5 (60) | 5/21 (24) | 38/94 (40) | .27 | |
| Death within 30 days of follow-up, N (%) | 1/10 (10) | 3/29 (10) | 4/69 (6) | .52 |
The only significant difference was between patients treated with ribavirin versus IVIG (P = .02).